Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=70 Randomized Treatment

Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery

Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT01212874 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour — 97.9; 45.6 mmHg*min/prebypass hour — p=0.21

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
nitroglycerin (Drug); esmolol (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Loma Linda University
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour		 97.9; 45.6 0.21
SECONDARY
Title: Systolic Hypertension		 48.6; 145.8 0.04 sig

Summary

This is an investigator initiated, sponsored, open label, prospective randomized controlled trial to be performed in adult patients undergoing scheduled cardiac surgery. Patients will be randomized to esmolol infusion or nitroglycerin infusion for control of hypertension that occurs during cardiac surgery from induction of anesthesia to initiation of cardiopulmonary bypass (CPB).

Eligibility Criteria

Inclusion Criteria

  • adult patients scheduled for cardiac surgery at LLUMC University Hospital will be eligible for participation in this study.

Exclusion Criteria

  • severe LV (left ventricle)dysfunction (EF < 35%).
  • emergency procedures.
  • procedures with combined carotid artery surgery.
  • patients at high risk for stroke.
  • hemodynamically significant dysrhythmias.
  • pre-existing atrial fibrillation or high degree AV (atrioventricular block).
  • pacemaker dependency.
  • known sensitivity to beta blockers.
  • patient refusal.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01212874). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search